Transhepatic Arterial Chemoembolization with Oxaliplatin-eluting Microspheres (OEM-TACE) for Unresectable Hepatic Tumors
Background: While conventional transhepatic arterial chemoembolization (TACE) is accepted worldwide as an effective treatment for patients with unresectable hepatocellular carcinoma (HCC), its use in other hepatic tumors is not supported by randomized studies. Preliminary results have shown that new...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2008-11, Vol.28 (6B), p.3835-3842 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3842 |
|---|---|
| container_issue | 6B |
| container_start_page | 3835 |
| container_title | Anticancer research |
| container_volume | 28 |
| creator | POGGI, Guido QUARETTI, Pietro MONTAGNA, Michela AMATU, Alessio TERAGNI, Cristina PALUMBO, Ilaria TRAVERSO, Elena TONINI, Stefano VILLANI, Laura SCELSI, Mario BAIARDI, Paola GRAZIA FELISI, Maria MINOIA, Claudio SOTTOTETTI, Federico TAGLIAFERRI, Barbara RICCARDI, Alberto BERNARDO, Giovanni REGAZZI BONORA, Mario GAGGERI, Raffaella RONCHI, Anna MASSA SALUZZO, Cesare AZZARETTI, Andrea RODOLICO, Giuseppe |
| description | Background: While conventional transhepatic arterial chemoembolization (TACE) is accepted worldwide as an effective treatment
for patients with unresectable hepatocellular carcinoma (HCC), its use in other hepatic tumors is not supported by randomized
studies. Preliminary results have shown that new drug-eluting microspheres (DEM) seem to optimize TACE procedures. The aim
of this study was to evaluate the capability of HepaSphere⢠to load oxaliplatin and their pharmacokinetic outcome. The feasibility
and safety of treatment with oxaliplatin-eluting microspheres (OEM-TACE) was also evaluated in patients with unresectable
liver metastasis of colorectal cancer and unresectable intrahepatic cholangiocarcinoma. Patients and Methods: An inductively
coupled plasma mass spectrometer (ICP-MS) was used to quantify the oxaliplatin bound to microspheres and the oxaliplatin in
liver biopsies. Fifteen patients (8 with colorectal carcinoma liver metastases, 7 with intrahepatic cholangiocarcinoma) were
treated with 27 sessions of OEM-TACE. Results: The data suggested that the microspheres can bind oxaliplatin entirely. The
pharmacokinetic parameters were significantly different between the OEM-TACE patients and a control group of patients treated
with oxaliplatin chemotherapy. The mean oxaliplatin concentration within the tumor was twenty-times higher than the extratumoral
liver concentration in the OEM-TACE patients. According to response evaluating criteria in solid tumors (RECIST), stable disease
was observed in 8 out of the 15 patients (53.3%), a partial response in 2 (13.3%) and intrahepatic or extrahepatic tumor progression
in 5 out of the 15 patients (33.3%). No major adverse event (AE G3/4) occurred. Conclusion: TACE with oxaliplatin-loaded microspheres
is a safe and feasible treatment without major adverse events and with a favorable pharmacokinetic profile. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_19192637</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19192637</sourcerecordid><originalsourceid>FETCH-LOGICAL-h270t-5bcfa73c04803d40716ff3ac96ddae40217d3141c8470a4be6fede79aa7370f73</originalsourceid><addsrcrecordid>eNo9kFFLwzAUhYMobk7_guRF0YdC0rRN8zjLdMLGXrrncpsmayRdS9Kx6a83sOnTgXO_ew6cKzSlXNCIp4xcoymJUxJxQtIJuvP-i5AsEzm7RRMqqIgzxqfoVDrY-1YNMBqJ525UzoDFRau6XnV1b81PuPR7fDRjizcnsGawwdlHyh6C7PDaSNf7oVVOefyyWayjcl4sXrHuHd7ug6nkCLVVeHkpKQ9d7_w9utFgvXq46Axt3xdlsYxWm4_PYr6K2piTMUprqYEzSZKcsCYhnGZaM5AiaxpQCYkpbxhNqMwTTiCpVaZVo7iA8MSJ5myGHs-5w6HuVFMNznTgvqu_CQLwdAHAS7A67CGN_-diIvJEhPIZej5zrdm1R-NU5TuwNsSyClycV9lbxXKWsl_zcnTK</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Transhepatic Arterial Chemoembolization with Oxaliplatin-eluting Microspheres (OEM-TACE) for Unresectable Hepatic Tumors</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>POGGI, Guido ; QUARETTI, Pietro ; MONTAGNA, Michela ; AMATU, Alessio ; TERAGNI, Cristina ; PALUMBO, Ilaria ; TRAVERSO, Elena ; TONINI, Stefano ; VILLANI, Laura ; SCELSI, Mario ; BAIARDI, Paola ; GRAZIA FELISI, Maria ; MINOIA, Claudio ; SOTTOTETTI, Federico ; TAGLIAFERRI, Barbara ; RICCARDI, Alberto ; BERNARDO, Giovanni ; REGAZZI BONORA, Mario ; GAGGERI, Raffaella ; RONCHI, Anna ; MASSA SALUZZO, Cesare ; AZZARETTI, Andrea ; RODOLICO, Giuseppe</creator><creatorcontrib>POGGI, Guido ; QUARETTI, Pietro ; MONTAGNA, Michela ; AMATU, Alessio ; TERAGNI, Cristina ; PALUMBO, Ilaria ; TRAVERSO, Elena ; TONINI, Stefano ; VILLANI, Laura ; SCELSI, Mario ; BAIARDI, Paola ; GRAZIA FELISI, Maria ; MINOIA, Claudio ; SOTTOTETTI, Federico ; TAGLIAFERRI, Barbara ; RICCARDI, Alberto ; BERNARDO, Giovanni ; REGAZZI BONORA, Mario ; GAGGERI, Raffaella ; RONCHI, Anna ; MASSA SALUZZO, Cesare ; AZZARETTI, Andrea ; RODOLICO, Giuseppe</creatorcontrib><description>Background: While conventional transhepatic arterial chemoembolization (TACE) is accepted worldwide as an effective treatment
for patients with unresectable hepatocellular carcinoma (HCC), its use in other hepatic tumors is not supported by randomized
studies. Preliminary results have shown that new drug-eluting microspheres (DEM) seem to optimize TACE procedures. The aim
of this study was to evaluate the capability of HepaSphere⢠to load oxaliplatin and their pharmacokinetic outcome. The feasibility
and safety of treatment with oxaliplatin-eluting microspheres (OEM-TACE) was also evaluated in patients with unresectable
liver metastasis of colorectal cancer and unresectable intrahepatic cholangiocarcinoma. Patients and Methods: An inductively
coupled plasma mass spectrometer (ICP-MS) was used to quantify the oxaliplatin bound to microspheres and the oxaliplatin in
liver biopsies. Fifteen patients (8 with colorectal carcinoma liver metastases, 7 with intrahepatic cholangiocarcinoma) were
treated with 27 sessions of OEM-TACE. Results: The data suggested that the microspheres can bind oxaliplatin entirely. The
pharmacokinetic parameters were significantly different between the OEM-TACE patients and a control group of patients treated
with oxaliplatin chemotherapy. The mean oxaliplatin concentration within the tumor was twenty-times higher than the extratumoral
liver concentration in the OEM-TACE patients. According to response evaluating criteria in solid tumors (RECIST), stable disease
was observed in 8 out of the 15 patients (53.3%), a partial response in 2 (13.3%) and intrahepatic or extrahepatic tumor progression
in 5 out of the 15 patients (33.3%). No major adverse event (AE G3/4) occurred. Conclusion: TACE with oxaliplatin-loaded microspheres
is a safe and feasible treatment without major adverse events and with a favorable pharmacokinetic profile.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 19192637</identifier><language>eng</language><publisher>Attiki: International Institute of Anticancer Research</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacokinetics ; Biological and medical sciences ; Chemoembolization, Therapeutic - adverse effects ; Chemoembolization, Therapeutic - methods ; Cholangiocarcinoma - metabolism ; Cholangiocarcinoma - therapy ; Drug Delivery Systems ; Feasibility Studies ; Female ; Hepatic Artery ; Humans ; Liver Neoplasms - metabolism ; Liver Neoplasms - therapy ; Male ; Medical sciences ; Microspheres ; Middle Aged ; Organoplatinum Compounds - administration & dosage ; Organoplatinum Compounds - adverse effects ; Organoplatinum Compounds - chemistry ; Organoplatinum Compounds - pharmacokinetics ; Survival Rate ; Tumors</subject><ispartof>Anticancer research, 2008-11, Vol.28 (6B), p.3835-3842</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20984980$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19192637$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>POGGI, Guido</creatorcontrib><creatorcontrib>QUARETTI, Pietro</creatorcontrib><creatorcontrib>MONTAGNA, Michela</creatorcontrib><creatorcontrib>AMATU, Alessio</creatorcontrib><creatorcontrib>TERAGNI, Cristina</creatorcontrib><creatorcontrib>PALUMBO, Ilaria</creatorcontrib><creatorcontrib>TRAVERSO, Elena</creatorcontrib><creatorcontrib>TONINI, Stefano</creatorcontrib><creatorcontrib>VILLANI, Laura</creatorcontrib><creatorcontrib>SCELSI, Mario</creatorcontrib><creatorcontrib>BAIARDI, Paola</creatorcontrib><creatorcontrib>GRAZIA FELISI, Maria</creatorcontrib><creatorcontrib>MINOIA, Claudio</creatorcontrib><creatorcontrib>SOTTOTETTI, Federico</creatorcontrib><creatorcontrib>TAGLIAFERRI, Barbara</creatorcontrib><creatorcontrib>RICCARDI, Alberto</creatorcontrib><creatorcontrib>BERNARDO, Giovanni</creatorcontrib><creatorcontrib>REGAZZI BONORA, Mario</creatorcontrib><creatorcontrib>GAGGERI, Raffaella</creatorcontrib><creatorcontrib>RONCHI, Anna</creatorcontrib><creatorcontrib>MASSA SALUZZO, Cesare</creatorcontrib><creatorcontrib>AZZARETTI, Andrea</creatorcontrib><creatorcontrib>RODOLICO, Giuseppe</creatorcontrib><title>Transhepatic Arterial Chemoembolization with Oxaliplatin-eluting Microspheres (OEM-TACE) for Unresectable Hepatic Tumors</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Background: While conventional transhepatic arterial chemoembolization (TACE) is accepted worldwide as an effective treatment
for patients with unresectable hepatocellular carcinoma (HCC), its use in other hepatic tumors is not supported by randomized
studies. Preliminary results have shown that new drug-eluting microspheres (DEM) seem to optimize TACE procedures. The aim
of this study was to evaluate the capability of HepaSphere⢠to load oxaliplatin and their pharmacokinetic outcome. The feasibility
and safety of treatment with oxaliplatin-eluting microspheres (OEM-TACE) was also evaluated in patients with unresectable
liver metastasis of colorectal cancer and unresectable intrahepatic cholangiocarcinoma. Patients and Methods: An inductively
coupled plasma mass spectrometer (ICP-MS) was used to quantify the oxaliplatin bound to microspheres and the oxaliplatin in
liver biopsies. Fifteen patients (8 with colorectal carcinoma liver metastases, 7 with intrahepatic cholangiocarcinoma) were
treated with 27 sessions of OEM-TACE. Results: The data suggested that the microspheres can bind oxaliplatin entirely. The
pharmacokinetic parameters were significantly different between the OEM-TACE patients and a control group of patients treated
with oxaliplatin chemotherapy. The mean oxaliplatin concentration within the tumor was twenty-times higher than the extratumoral
liver concentration in the OEM-TACE patients. According to response evaluating criteria in solid tumors (RECIST), stable disease
was observed in 8 out of the 15 patients (53.3%), a partial response in 2 (13.3%) and intrahepatic or extrahepatic tumor progression
in 5 out of the 15 patients (33.3%). No major adverse event (AE G3/4) occurred. Conclusion: TACE with oxaliplatin-loaded microspheres
is a safe and feasible treatment without major adverse events and with a favorable pharmacokinetic profile.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Chemoembolization, Therapeutic - adverse effects</subject><subject>Chemoembolization, Therapeutic - methods</subject><subject>Cholangiocarcinoma - metabolism</subject><subject>Cholangiocarcinoma - therapy</subject><subject>Drug Delivery Systems</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Hepatic Artery</subject><subject>Humans</subject><subject>Liver Neoplasms - metabolism</subject><subject>Liver Neoplasms - therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Microspheres</subject><subject>Middle Aged</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Organoplatinum Compounds - chemistry</subject><subject>Organoplatinum Compounds - pharmacokinetics</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kFFLwzAUhYMobk7_guRF0YdC0rRN8zjLdMLGXrrncpsmayRdS9Kx6a83sOnTgXO_ew6cKzSlXNCIp4xcoymJUxJxQtIJuvP-i5AsEzm7RRMqqIgzxqfoVDrY-1YNMBqJ525UzoDFRau6XnV1b81PuPR7fDRjizcnsGawwdlHyh6C7PDaSNf7oVVOefyyWayjcl4sXrHuHd7ug6nkCLVVeHkpKQ9d7_w9utFgvXq46Axt3xdlsYxWm4_PYr6K2piTMUprqYEzSZKcsCYhnGZaM5AiaxpQCYkpbxhNqMwTTiCpVaZVo7iA8MSJ5myGHs-5w6HuVFMNznTgvqu_CQLwdAHAS7A67CGN_-diIvJEhPIZej5zrdm1R-NU5TuwNsSyClycV9lbxXKWsl_zcnTK</recordid><startdate>20081101</startdate><enddate>20081101</enddate><creator>POGGI, Guido</creator><creator>QUARETTI, Pietro</creator><creator>MONTAGNA, Michela</creator><creator>AMATU, Alessio</creator><creator>TERAGNI, Cristina</creator><creator>PALUMBO, Ilaria</creator><creator>TRAVERSO, Elena</creator><creator>TONINI, Stefano</creator><creator>VILLANI, Laura</creator><creator>SCELSI, Mario</creator><creator>BAIARDI, Paola</creator><creator>GRAZIA FELISI, Maria</creator><creator>MINOIA, Claudio</creator><creator>SOTTOTETTI, Federico</creator><creator>TAGLIAFERRI, Barbara</creator><creator>RICCARDI, Alberto</creator><creator>BERNARDO, Giovanni</creator><creator>REGAZZI BONORA, Mario</creator><creator>GAGGERI, Raffaella</creator><creator>RONCHI, Anna</creator><creator>MASSA SALUZZO, Cesare</creator><creator>AZZARETTI, Andrea</creator><creator>RODOLICO, Giuseppe</creator><general>International Institute of Anticancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20081101</creationdate><title>Transhepatic Arterial Chemoembolization with Oxaliplatin-eluting Microspheres (OEM-TACE) for Unresectable Hepatic Tumors</title><author>POGGI, Guido ; QUARETTI, Pietro ; MONTAGNA, Michela ; AMATU, Alessio ; TERAGNI, Cristina ; PALUMBO, Ilaria ; TRAVERSO, Elena ; TONINI, Stefano ; VILLANI, Laura ; SCELSI, Mario ; BAIARDI, Paola ; GRAZIA FELISI, Maria ; MINOIA, Claudio ; SOTTOTETTI, Federico ; TAGLIAFERRI, Barbara ; RICCARDI, Alberto ; BERNARDO, Giovanni ; REGAZZI BONORA, Mario ; GAGGERI, Raffaella ; RONCHI, Anna ; MASSA SALUZZO, Cesare ; AZZARETTI, Andrea ; RODOLICO, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h270t-5bcfa73c04803d40716ff3ac96ddae40217d3141c8470a4be6fede79aa7370f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Chemoembolization, Therapeutic - adverse effects</topic><topic>Chemoembolization, Therapeutic - methods</topic><topic>Cholangiocarcinoma - metabolism</topic><topic>Cholangiocarcinoma - therapy</topic><topic>Drug Delivery Systems</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Hepatic Artery</topic><topic>Humans</topic><topic>Liver Neoplasms - metabolism</topic><topic>Liver Neoplasms - therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Microspheres</topic><topic>Middle Aged</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Organoplatinum Compounds - chemistry</topic><topic>Organoplatinum Compounds - pharmacokinetics</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>POGGI, Guido</creatorcontrib><creatorcontrib>QUARETTI, Pietro</creatorcontrib><creatorcontrib>MONTAGNA, Michela</creatorcontrib><creatorcontrib>AMATU, Alessio</creatorcontrib><creatorcontrib>TERAGNI, Cristina</creatorcontrib><creatorcontrib>PALUMBO, Ilaria</creatorcontrib><creatorcontrib>TRAVERSO, Elena</creatorcontrib><creatorcontrib>TONINI, Stefano</creatorcontrib><creatorcontrib>VILLANI, Laura</creatorcontrib><creatorcontrib>SCELSI, Mario</creatorcontrib><creatorcontrib>BAIARDI, Paola</creatorcontrib><creatorcontrib>GRAZIA FELISI, Maria</creatorcontrib><creatorcontrib>MINOIA, Claudio</creatorcontrib><creatorcontrib>SOTTOTETTI, Federico</creatorcontrib><creatorcontrib>TAGLIAFERRI, Barbara</creatorcontrib><creatorcontrib>RICCARDI, Alberto</creatorcontrib><creatorcontrib>BERNARDO, Giovanni</creatorcontrib><creatorcontrib>REGAZZI BONORA, Mario</creatorcontrib><creatorcontrib>GAGGERI, Raffaella</creatorcontrib><creatorcontrib>RONCHI, Anna</creatorcontrib><creatorcontrib>MASSA SALUZZO, Cesare</creatorcontrib><creatorcontrib>AZZARETTI, Andrea</creatorcontrib><creatorcontrib>RODOLICO, Giuseppe</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>POGGI, Guido</au><au>QUARETTI, Pietro</au><au>MONTAGNA, Michela</au><au>AMATU, Alessio</au><au>TERAGNI, Cristina</au><au>PALUMBO, Ilaria</au><au>TRAVERSO, Elena</au><au>TONINI, Stefano</au><au>VILLANI, Laura</au><au>SCELSI, Mario</au><au>BAIARDI, Paola</au><au>GRAZIA FELISI, Maria</au><au>MINOIA, Claudio</au><au>SOTTOTETTI, Federico</au><au>TAGLIAFERRI, Barbara</au><au>RICCARDI, Alberto</au><au>BERNARDO, Giovanni</au><au>REGAZZI BONORA, Mario</au><au>GAGGERI, Raffaella</au><au>RONCHI, Anna</au><au>MASSA SALUZZO, Cesare</au><au>AZZARETTI, Andrea</au><au>RODOLICO, Giuseppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Transhepatic Arterial Chemoembolization with Oxaliplatin-eluting Microspheres (OEM-TACE) for Unresectable Hepatic Tumors</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2008-11-01</date><risdate>2008</risdate><volume>28</volume><issue>6B</issue><spage>3835</spage><epage>3842</epage><pages>3835-3842</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>Background: While conventional transhepatic arterial chemoembolization (TACE) is accepted worldwide as an effective treatment
for patients with unresectable hepatocellular carcinoma (HCC), its use in other hepatic tumors is not supported by randomized
studies. Preliminary results have shown that new drug-eluting microspheres (DEM) seem to optimize TACE procedures. The aim
of this study was to evaluate the capability of HepaSphere⢠to load oxaliplatin and their pharmacokinetic outcome. The feasibility
and safety of treatment with oxaliplatin-eluting microspheres (OEM-TACE) was also evaluated in patients with unresectable
liver metastasis of colorectal cancer and unresectable intrahepatic cholangiocarcinoma. Patients and Methods: An inductively
coupled plasma mass spectrometer (ICP-MS) was used to quantify the oxaliplatin bound to microspheres and the oxaliplatin in
liver biopsies. Fifteen patients (8 with colorectal carcinoma liver metastases, 7 with intrahepatic cholangiocarcinoma) were
treated with 27 sessions of OEM-TACE. Results: The data suggested that the microspheres can bind oxaliplatin entirely. The
pharmacokinetic parameters were significantly different between the OEM-TACE patients and a control group of patients treated
with oxaliplatin chemotherapy. The mean oxaliplatin concentration within the tumor was twenty-times higher than the extratumoral
liver concentration in the OEM-TACE patients. According to response evaluating criteria in solid tumors (RECIST), stable disease
was observed in 8 out of the 15 patients (53.3%), a partial response in 2 (13.3%) and intrahepatic or extrahepatic tumor progression
in 5 out of the 15 patients (33.3%). No major adverse event (AE G3/4) occurred. Conclusion: TACE with oxaliplatin-loaded microspheres
is a safe and feasible treatment without major adverse events and with a favorable pharmacokinetic profile.</abstract><cop>Attiki</cop><pub>International Institute of Anticancer Research</pub><pmid>19192637</pmid><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2008-11, Vol.28 (6B), p.3835-3842 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_pubmed_primary_19192637 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Aged, 80 and over Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacokinetics Biological and medical sciences Chemoembolization, Therapeutic - adverse effects Chemoembolization, Therapeutic - methods Cholangiocarcinoma - metabolism Cholangiocarcinoma - therapy Drug Delivery Systems Feasibility Studies Female Hepatic Artery Humans Liver Neoplasms - metabolism Liver Neoplasms - therapy Male Medical sciences Microspheres Middle Aged Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Organoplatinum Compounds - chemistry Organoplatinum Compounds - pharmacokinetics Survival Rate Tumors |
| title | Transhepatic Arterial Chemoembolization with Oxaliplatin-eluting Microspheres (OEM-TACE) for Unresectable Hepatic Tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T02%3A04%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Transhepatic%20Arterial%20Chemoembolization%20with%20Oxaliplatin-eluting%20Microspheres%20(OEM-TACE)%20for%20Unresectable%20Hepatic%20Tumors&rft.jtitle=Anticancer%20research&rft.au=POGGI,%20Guido&rft.date=2008-11-01&rft.volume=28&rft.issue=6B&rft.spage=3835&rft.epage=3842&rft.pages=3835-3842&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E19192637%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19192637&rfr_iscdi=true |